Humacyte Reports Q3 2026 Revenue Growth Driven by Symvess Adoption
Humacyte (HUMA) reported significant sequential growth for the third quarter of 2026, with product revenue reaching $1 million—a 151% increase over the second quarter. This surge is attributed to the expanding adoption of its Symvess product, which saw hospital orders grow from 34 to 49 institutions during the period. Management expressed optimism for the fourth quarter, projecting that sales could at least double third-quarter results based on current trends. Financially, the company improved its net loss to $15.5 million, down from a $17.5 million loss in the prior year, aided by reduced research and development expenses and lower inventory production costs. While unused production capacity continues to impact cost of goods sold, Humacyte is moving forward with regulatory milestones, including a planned supplemental Biologics License Application for dialysis access in November 2026.
Tickers: $HUMA
Topics: Cash Flow Management Hospital Adoption Product Revenue Growth Revenue Guidance